0001104659-21-006328.txt : 20210121
0001104659-21-006328.hdr.sgml : 20210121
20210121163124
ACCESSION NUMBER: 0001104659-21-006328
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210120
FILED AS OF DATE: 20210121
DATE AS OF CHANGE: 20210121
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Smith L. Mary
CENTRAL INDEX KEY: 0001787013
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 21542368
MAIL ADDRESS:
STREET 1: C/O SPRINGWORKS THERAPEUTICS, INC.
STREET 2: 100 WASHINGTON BLVD.
CITY: STAMFORD
STATE: CT
ZIP: 06902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
4
1
tm213781d2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-01-20
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001787013
Smith L. Mary
C/O SPRINGWORKS THERAPEUTICS, INC.
100 WASHINGTON BLVD.
STAMFORD
CT
06902
0
1
0
0
Chief Development Officer
Common Stock
2021-01-20
4
M
0
1128
1.65
A
168639
D
Common Stock
2021-01-20
4
M
0
8872
2.30
A
177511
D
Common Stock
2021-01-20
4
S
0
10000
78.7016
D
167511
D
Stock Option (Right to Buy)
1.65
2021-01-20
4
M
0
1128
0
D
2029-03-19
Common Stock
1128
1451
D
Stock Option (Right to Buy)
2.30
2021-01-20
4
M
0
8872
0
D
2029-04-22
Common Stock
8872
114296
D
The stock option exercises and sale transactions reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in prices ranging from $77.83 to $79.24, inclusive.
Includes 167,511 restricted stock awards which are subject to forfeiture until they vest.
25% of this option vested and became exercisable on March 19, 2020. The remainder vests and becomes exercisable in 36 equal monthly installments thereafter.
This option began to vest and become exercisable in 48 equal monthly installments beginning on April 22, 2019.
/s/ Francis I. Perier, Jr as Attorney-in-Fact
2021-01-21